Small intestine adenocarcinoma
diseaseOn this page
Also known as adenocarcinoma - small intest.adenocarcinoma of small boweladenocarcinoma of small intestineadenocarcinoma of the small boweladenocarcinoma of the small intestinesmall bowel adenocarcinomasmall intestinal adenocarcinoma
Summary
Small intestine adenocarcinoma (MONDO:0003198) is a disease and 26 clinical trials. Top therapeutic interventions include oxaliplatin, cobimetinib, and dostarlimab. A subtype of adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
- Clinical trials: 26
Clinical features
Epidemiology
Prevalence records
25 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.588 | Europe | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.517 | Austria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.734 | Belgium | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.174 | Bulgaria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.308 | Croatia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.464 | Czech Republic | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.36 | Estonia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.574 | Finland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.657 | France | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.551 | Germany | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.724 | Iceland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.564 | Ireland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.79 | Italy | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.265 | Latvia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.277 | Lithuania | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.377 | Malta | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.788 | Norway | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.219 | Poland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.743 | Portugal | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.462 | Slovakia | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | small intestine adenocarcinoma |
| Mondo ID | MONDO:0003198 |
| EFO | EFO:1000532 |
| Orphanet | 104075 |
| DOID | DOID:4906 |
| ICD-11 | 1369513329 |
| NCIT | C7888 |
| SNOMED CT | 424440001 |
| UMLS | C0278803 |
| MedGen | 82984 |
| GARD | 0019851 |
| Anatomy (UBERON) | UBERON:0002108 |
| Is cancer (heuristic) | no |
Also known as: adenocarcinoma - small intest. · adenocarcinoma of small bowel · adenocarcinoma of small intestine · adenocarcinoma of the small bowel · adenocarcinoma of the small intestine · small bowel adenocarcinoma · small intestinal adenocarcinoma · small intestine adenocarcinoma
Data availability: 3 cell lines.
Disease family
This is a subtype of adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › small intestine adenocarcinoma
Related subtypes (63): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, ovarian adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, gastroesophageal junction adenocarcinoma, maxillary sinus adenocarcinoma, mucinous adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, cervical adenocarcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, poorly differentiated thyroid gland carcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, gastroesophageal adenocarcinoma, adenoacanthoma
Subtypes (2): jejunal adenocarcinoma, duodenal adenocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 26.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 12 |
| Not specified | 7 |
| PHASE1 | 5 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02502370 | PHASE3 | UNKNOWN | Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma |
| NCT04257461 | PHASE3 | UNKNOWN | A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma |
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT02949219 | PHASE2 | ACTIVE_NOT_RECRUITING | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery |
| NCT04111172 | PHASE2 | ACTIVE_NOT_RECRUITING | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma |
| NCT04205968 | PHASE2 | RECRUITING | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers |
| NCT04729322 | PHASE2 | ACTIVE_NOT_RECRUITING | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders |
| NCT05472948 | PHASE2 | RECRUITING | Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma |
| NCT06333314 | PHASE2 | RECRUITING | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI |
| NCT06835387 | PHASE2 | RECRUITING | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors |
| NCT07347314 | PHASE2 | RECRUITING | Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy |
| NCT00433550 | PHASE2 | COMPLETED | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer |
| NCT01208103 | PHASE2 | COMPLETED | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma |
| NCT03108131 | PHASE2 | COMPLETED | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors |
| NCT07417488 | PHASE1 | RECRUITING | GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas |
| NCT00004074 | PHASE1 | COMPLETED | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
| NCT00031681 | PHASE1 | COMPLETED | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
| NCT00397384 | PHASE1 | COMPLETED | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer |
| NCT04164069 | PHASE1 | COMPLETED | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab |
| NCT05704010 | Not specified | RECRUITING | Videocapsule Endoscopy in Lynch Syndrome |
| NCT06234306 | Not specified | RECRUITING | Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care |
| NCT07472686 | Not specified | RECRUITING | Small Bowel Capsule Endoscopy in Lynch Syndrome |
| NCT00087191 | Not specified | TERMINATED | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer |
| NCT02976090 | Not specified | COMPLETED | Phenotyping of Small Bowel Adenocarcinoma |
| NCT03771508 | Not specified | COMPLETED | Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA) |
| NCT05450393 | Not specified | WITHDRAWN | Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| OXALIPLATIN | 4 | 5 |
| COBIMETINIB | 4 | 1 |
| DOSTARLIMAB | 4 | 1 |
| ENFORTUMAB VEDOTIN | 4 | 1 |
| NEOMYCIN | 4 | 1 |
| RAMUCIRUMAB | 4 | 1 |
| FRAMYCETIN | 3 | 1 |
| SURUFATINIB | 3 | 1 |
| EDODEKIN ALFA | 2 | 1 |
| UCN-01 | 2 | 1 |
| CHEMBL4538425 | 0 | 1 |
| CHEMBL3754093 | 0 | 1 |
| CHEMBL4299247 | 0 | 1 |
| CHEMBL1236539 | 0 | 1 |
| MOTEXAFIN LUTETIUM | -1 | 1 |